If you or someone you love relies on Medicare and is struggling with obesity, you’ve probably asked this question: does Medicare cover weight loss medication? The answer has changed significantly in 2026 — and understanding the new rules could save you thousands of dollars a year. This guide breaks down everything you need to know, from the historic federal restrictions to the brand-new Medicare GLP-1 Bridge program launching this summer.
Why Medicare Has Historically NOT Covered Weight Loss Drugs
For decades, the answer to “does Medicare cover weight loss medication” was a flat-out no. Federal law — specifically the Social Security Act — explicitly prohibits Medicare Part D from covering drugs used solely for weight loss. This statutory ban has been in place since Medicare Part D was created in 2006.
As a result, even as GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Zepbound revolutionized obesity treatment, millions of Medicare beneficiaries were left without coverage — even when their doctors prescribed these medications for weight management.
That is now beginning to change.
The Big News: Medicare GLP-1 Bridge Program (July 2026)
What Is the Medicare GLP-1 Bridge?
The Centers for Medicare & Medicaid Services (CMS) has announced a landmark short-term program called the Medicare GLP-1 Bridge, set to launch July 1, 2026, and run through December 31, 2027. This is specifically designed to bridge the coverage gap while a longer-term program — the BALANCE Model — is developed.
Under this program, eligible Medicare Part D beneficiaries will be able to access FDA-approved GLP-1 weight loss medications for just $50 per month, a fraction of the retail cost which can run anywhere from $149 to over $699 per month without coverage.
The program operates outside of the standard Part D benefit payment structure, meaning Part D plan sponsors do not have to opt in — eligible beneficiaries in qualifying plans gain access automatically.
Which Weight Loss Drugs Are Covered Under the Medicare GLP-1 Bridge?
CMS has confirmed three medications are covered under the Medicare GLP-1 Bridge when prescribed specifically for weight reduction:
- Wegovy (semaglutide) — all formulations, both injectable and tablet
- Zepbound (tirzepatide) — the KwikPen formulation only (single-dose vial and single-dose pen are NOT included)
- Foundayo — all formulations (added to the list following FDA approval on April 6, 2026)
Important: Ozempic and Mounjaro are NOT covered under the Bridge for weight loss. These drugs carry diabetes indications rather than weight-loss indications, so they fall under the standard Part D formulary rules. Your plan may cover them for diabetes management — but not through this new Bridge program.
Who Qualifies for the Medicare GLP-1 Bridge?
To be eligible for the $50/month coverage, you must meet all of the following criteria:
Enrollment Requirements:
- Be actively enrolled in a standalone Medicare Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD) for calendar year 2026
- Beneficiaries in Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), and the LI NET program are also eligible
Clinical Eligibility (BMI-Based):
- A Body Mass Index (BMI) of 35 or higher, regardless of other conditions — OR —
- A BMI of 27 or higher plus at least one qualifying clinical condition (such as prediabetes, type 2 diabetes, hypertension, or cardiovascular disease, among others)
Prior Authorization: Coverage is not automatic. Your healthcare provider must submit a prior authorization request demonstrating you meet the clinical criteria. CMS has indicated it will release the Medicare GLP-1 Bridge prior authorization fax form and detailed processes in June 2026.
Key Exclusion: If you are prescribed Wegovy for cardiovascular risk reduction, or Zepbound for obstructive sleep apnea — both of which are already separately coverable under standard Part D — you do NOT qualify for Bridge coverage for that specific drug. Standard Part D formulary rules apply instead.
What About the BALANCE Model — What Comes After the Bridge?
The Bridge is a temporary fix. The longer-term plan is the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a multi-year CMS demonstration program. Here’s the current status:
- CMS announced the BALANCE Model on December 23, 2025
- Medicaid coverage under BALANCE began as early as May 2026
- The Medicare Part D portion under BALANCE was originally set to begin January 2027, but in April 2026, CMS announced a delay of the Medicare Part D component to Calendar Year 2027 at the earliest
- Under BALANCE, CMS has negotiated directly with Novo Nordisk and Eli Lilly, and the following medications are included: all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, and the KwikPen formulation of Zepbound
The BALANCE Model is broader in scope — it includes lifestyle modification supports alongside medication access, and is designed as a sustainable, long-term coverage solution.
What Does Medicare Currently Cover for Weight Loss (Before July 2026)?
While pure weight loss drug coverage has been prohibited, Medicare does currently cover GLP-1 drugs in certain situations and provides some related services:
GLP-1 Drugs Covered Under Standard Part D
| Drug | Covered Condition |
|---|---|
| Ozempic / Rybelsus (semaglutide) | Type 2 diabetes management |
| Mounjaro (tirzepatide) | Type 2 diabetes management |
| Wegovy (semaglutide) | Cardiovascular risk reduction in adults with established heart disease who are overweight/obese |
| Zepbound (tirzepatide) | Moderate-to-severe obstructive sleep apnea in adults with obesity |
Coverage depends on your specific plan’s formulary, and prior authorization is nearly universal.
Medicare Part B: Obesity Counseling
Medicare Part B covers Intensive Behavioral Therapy (IBT) for Obesity at no cost (when you see a primary care doctor who accepts Medicare assignment). This includes:
- One face-to-face visit per week for the first month
- One visit every two weeks for months 2–6
- One visit per month for months 7–12 if you meet a 3kg weight loss goal in the first six months
Out-of-Pocket Cost Cap
In 2026, Medicare Part D caps yearly out-of-pocket spending on covered drugs at $2,100. Once you reach that threshold, your covered drugs cost nothing for the rest of the year.
What Did the Trump Administration Decide About Broader Coverage?
In the 2026 Medicare Part D Final Rule, the Trump Administration declined to extend broad Medicare weight loss drug coverage to all people with obesity — a proposal that had been included in the Biden Administration’s 2026 proposed rule. The administration stated the proposal “is not appropriate at this time,” though HHS leadership has sent mixed signals: HHS Secretary Robert F. Kennedy Jr. has criticized GLP-1 drugs, while CMS Administrator Mehmet Oz has publicly praised their benefits.
The Medicare GLP-1 Bridge, however, represents a significant policy compromise — a targeted, time-limited program that expands access while broader policy debates continue.
How to Access the Medicare GLP-1 Bridge When It Launches
Here are the steps to get coverage starting July 1, 2026:
- Confirm you’re enrolled in a Part D plan — standalone PDP or MA-PD plan for 2026
- Talk to your doctor about whether your BMI and health conditions meet the clinical criteria
- Get a prescription for Wegovy, Zepbound (KwikPen), or Foundayo for weight management
- Your provider submits prior authorization — the PA fax form will be released by CMS in June 2026
- Fill your prescription at your participating pharmacy for a $50 copay per monthly supply
- Note: Manufacturer coupons and discount cards cannot be applied to Medicare GLP-1 Bridge claims
If you have questions or need help, call Medicare directly at 1-800-633-4227 (1-800-MEDICARE) or contact your Part D plan provider.
How Much Could You Save?
Here’s a quick comparison of what these drugs cost without coverage versus through the Bridge:
| Medication | Typical Monthly Cash Price | Medicare GLP-1 Bridge Copay |
|---|---|---|
| Wegovy (injectable) | $499–$699 | $50 |
| Wegovy (pill) | $149+ | $50 |
| Zepbound (KwikPen) | $499–$649 | $50 |
| Foundayo | Varies | $50 |
That’s a potential savings of $400–$650 per month, or up to $7,800 per year.
Frequently Asked Questions
Q: Does Medicare cover Ozempic for weight loss? No. Ozempic is only covered under standard Part D when prescribed for type 2 diabetes. It is not included in the Medicare GLP-1 Bridge because it carries a diabetes — not weight loss — FDA indication.
Q: Does Medicare Advantage cover weight loss drugs? Medicare Advantage plans that include Part D drug coverage (MA-PD) are included in the GLP-1 Bridge program. However, coverage for weight loss drugs under standard MA plans has been excluded just like traditional Medicare — the Bridge changes this for eligible enrollees starting July 2026.
Q: Will Medicare cover weight loss surgery? Medicare Part A may cover bariatric surgery (such as gastric bypass or sleeve gastrectomy) if you have a BMI of 35 or higher with at least one obesity-related condition, and if performed at a certified facility. This is separate from drug coverage.
Q: Is the Bridge program available in all states? Yes. The Medicare GLP-1 Bridge is a nationwide demonstration program available in all states and territories.
Q: What happens after December 31, 2027, when the Bridge ends? CMS intends for the BALANCE Model to provide a longer-term solution. However, details for 2028 and beyond depend on ongoing policy decisions, congressional action, and model outcomes.
The Bottom Line
For most of Medicare’s history, the answer to “does Medicare cover weight loss medication” has been no — but 2026 marks a turning point. The Medicare GLP-1 Bridge launching July 1, 2026 will give eligible Part D beneficiaries access to Wegovy, Zepbound (KwikPen), and Foundayo for just $50 per month. While it’s a temporary, targeted program, it represents the most significant expansion of Medicare obesity drug coverage in the program’s history — and could be a life-changing development for the millions of Medicare beneficiaries living with obesity.
Talk to your doctor today, review your Part D enrollment, and make sure you’re ready when the Bridge opens on July 1, 2026.
Have questions about your Medicare plan and weight loss coverage? Drop them in the comments below — we read every one — and bookmark this page because coverage details are still being finalized and we’ll update it the moment CMS releases new information!